| Nome |
# |
|
Liquid biopsy in non-small cell lung cancer: highlights and challenges, file e2188be7-ef5e-4564-e053-6605fe0a49d6
|
57
|
|
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients, file e2188be7-ee98-4564-e053-6605fe0a49d6
|
54
|
|
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?, file e2188be7-e82f-4564-e053-6605fe0a49d6
|
52
|
|
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy, file e2188be7-e897-4564-e053-6605fe0a49d6
|
50
|
|
Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab., file e2188be7-efe8-4564-e053-6605fe0a49d6
|
47
|
|
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab, file e2188be7-f16f-4564-e053-6605fe0a49d6
|
45
|
|
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab, file e2188be7-ee30-4564-e053-6605fe0a49d6
|
42
|
|
Downregulation of
miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with
unresected malignant pleural mesothelioma, file e2188be7-eeeb-4564-e053-6605fe0a49d6
|
42
|
|
reply to the letter to the editor by C.Nicolazzo et al.: "circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy", file e2188be7-f2c8-4564-e053-6605fe0a49d6
|
42
|
|
Tumor microenvironment as a potential source of
clinical biomarkers in non-small cell lung cancer: can we use enemy territory at
our advantage?, file e2188be7-fc29-4564-e053-6605fe0a49d6
|
41
|
|
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy, file e2188be7-e717-4564-e053-6605fe0a49d6
|
40
|
|
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy, file e2188be7-e8eb-4564-e053-6605fe0a49d6
|
40
|
|
Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients, file e2188be7-ee90-4564-e053-6605fe0a49d6
|
36
|
|
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation, file e2188be7-e89c-4564-e053-6605fe0a49d6
|
35
|
|
Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System, file e2188be7-f11e-4564-e053-6605fe0a49d6
|
35
|
|
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743, file 2cb83594-f493-4382-8bbd-e9001b09e645
|
30
|
|
Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer, file 63aaf31f-2c97-4a8c-9b66-c2546c8e0467
|
22
|
|
Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib, file e2188be8-29dc-4564-e053-6605fe0a49d6
|
19
|
|
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer, file e2188be7-e8a2-4564-e053-6605fe0a49d6
|
18
|
|
Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach, file 0ddd2f78-0e31-4c1d-8bac-db7d2de44c74
|
16
|
|
Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis, file 359e63b4-b537-4e65-9e3e-05c4427d1cd0
|
16
|
|
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy, file e2188be8-3089-4564-e053-6605fe0a49d6
|
16
|
|
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells, file 5f2c71ee-c60d-40bb-9a8f-0b7e9222722a
|
14
|
|
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC):an18F-FDG PET/CT study, file e2188be7-e771-4564-e053-6605fe0a49d6
|
14
|
|
Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study, file 469b3f10-1dfa-404d-a3a7-e19d540cbfd8
|
13
|
|
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy, file e2188be7-e8a0-4564-e053-6605fe0a49d6
|
13
|
|
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC, file 0cc2d89a-b606-469c-951f-44c432bcc197
|
12
|
|
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer, file b2a78d7c-59e0-4d55-a098-df7184b40130
|
12
|
|
Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?, file 840b5915-3c6c-4dd0-94bc-150db86886ad
|
11
|
|
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status, file 96be58c7-1a02-46a5-988f-ed28a4458cbe
|
11
|
|
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study, file a3cdbba8-ab74-4a5e-8fc0-10393126ff6e
|
11
|
|
Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification, file 6dff7e30-0edc-49d0-8d71-56deed00d292
|
10
|
|
Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014), file e2188be7-e77f-4564-e053-6605fe0a49d6
|
9
|
|
Exosomes: a new horizon in lung cancer, file e2188be7-e89e-4564-e053-6605fe0a49d6
|
9
|
|
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT), file 6b33d02b-722d-4b40-b20b-28a53d712044
|
8
|
|
Tag-based next generation sequencing: A feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients, file c9eb5a9a-96d3-42ee-a042-07198f335bd5
|
8
|
|
Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis, file 646b1fbe-e49e-41dc-a535-3161096374fa
|
7
|
|
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer, file e2188be7-ee38-4564-e053-6605fe0a49d6
|
7
|
|
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges, file de0515bc-d0ae-45c9-a19f-ceb3bfbab8b6
|
6
|
|
Vinflunine for the treatment of non-small cell lung cancer, file e2188be7-e712-4564-e053-6605fe0a49d6
|
6
|
|
Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy, file 51a3fc51-c1e3-45d9-a201-5feb593db828
|
5
|
|
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer, file e2188be7-e711-4564-e053-6605fe0a49d6
|
5
|
|
Afatinib for the treatment of non-small cell lung cancer, file e2188be7-e714-4564-e053-6605fe0a49d6
|
5
|
|
PCSK9 is a promising prognostic marker in patients with advanced NSCLC, file e2188be7-eec9-4564-e053-6605fe0a49d6
|
5
|
|
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer, file c785209b-d118-4276-a27f-02a7bd1417d3
|
4
|
|
Investigational drugs
targeting fibroblast growth factor receptor in the treatment of non-small cell
lung cancer, file e2188be7-f5f6-4564-e053-6605fe0a49d6
|
4
|
|
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases, file e915b043-a794-45d9-a9a9-a982239d1c63
|
4
|
|
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial, file 4bf5d321-649e-4f6d-8d53-dc8b9a58f173
|
3
|
|
Belagenpumatucel-L for the treatment of non-small cell lung cancer, file a3989cfb-7f32-40bd-af31-f043bd98e4e9
|
3
|
|
Inserimento degli inibitori del checkpoint nell’algoritmo decisionale del carcinoma polmonare non a piccole cellule in stadio avanzato, file b4ec9013-0af2-4925-8cba-63d983a9d264
|
3
|
|
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus, file e2188be7-e713-4564-e053-6605fe0a49d6
|
3
|
|
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition, file e2188be7-e8f9-4564-e053-6605fe0a49d6
|
3
|
|
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019), file e2188be7-ee9a-4564-e053-6605fe0a49d6
|
3
|
|
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer, file e2188be7-f280-4564-e053-6605fe0a49d6
|
3
|
|
Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers, file e224377d-9a96-472b-8019-07555edfcb32
|
3
|
|
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer, file e4c8593a-a035-419f-8cd0-74c6a4d79d4f
|
3
|
|
Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy, file 1be8041d-69ff-4692-a241-04e44a703fb7
|
2
|
|
Use of nivolumab in elderly patients with advanced squamous non–small-cell lung cancer: results from the Italian cohort of an expanded access programme, file 31f9eb9d-4b3e-4f55-a00e-c3c710181aa3
|
2
|
|
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial, file 40116d3b-c963-4ec2-906f-d2c996c314f7
|
2
|
|
NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer, file c463584b-4785-4271-93a7-037b12f70541
|
2
|
|
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds, file e2188be7-e716-4564-e053-6605fe0a49d6
|
2
|
|
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression, file e2188be7-e833-4564-e053-6605fe0a49d6
|
2
|
|
Identification and management of immune checkpoint inhibitor-related myocarditis: use troponin wisely, file e2188be7-e8f2-4564-e053-6605fe0a49d6
|
2
|
|
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial, file e2188be7-e8f4-4564-e053-6605fe0a49d6
|
2
|
|
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study, file e2188be7-ee34-4564-e053-6605fe0a49d6
|
2
|
|
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine, file e2188be7-eec7-4564-e053-6605fe0a49d6
|
2
|
|
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors, file e2188be7-eeea-4564-e053-6605fe0a49d6
|
2
|
|
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer, file e2188be7-eeec-4564-e053-6605fe0a49d6
|
2
|
|
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis, file e2188be7-f49f-4564-e053-6605fe0a49d6
|
2
|
|
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, file e2188be7-f91a-4564-e053-6605fe0a49d6
|
2
|
|
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy, file e2188be8-27de-4564-e053-6605fe0a49d6
|
2
|
|
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial, file 05647d6e-2635-4a61-b0cd-efa663033f96
|
1
|
|
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects, file 1a69d185-248c-4f92-99f2-712569455b5b
|
1
|
|
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation, file 362419e9-8881-40e9-aafb-de1fa4379d1f
|
1
|
|
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study, file 65a0ab94-0af1-4fdf-8e2a-80a4fcf9100b
|
1
|
|
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population, file 6831205c-1875-443f-92f3-ebd3480fc896
|
1
|
|
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial, file 7b2456cb-483f-4359-974a-a6f164746efc
|
1
|
|
Understanding the checkpoint blockade in lung cancer immunotherapy, file e2188be7-f11a-4564-e053-6605fe0a49d6
|
1
|
|
Prognostic and predictive
relevance of circulating tumor cells in patients with non-small-cell lung cancer, file e2188be7-f1d3-4564-e053-6605fe0a49d6
|
1
|
|
Looking for results in non-small-cell lung
cancer: is bio-chemotherapy the right answer?, file e2188be7-f2c6-4564-e053-6605fe0a49d6
|
1
|
|
Hematopoietic growth factors in lung cancer, file e2188be7-f2c7-4564-e053-6605fe0a49d6
|
1
|
|
Releasing the brake: safety profile of immune check-point inhibitors in non-small
cell lung cancer, file e2188be7-f2cd-4564-e053-6605fe0a49d6
|
1
|
|
Recent advances in squamous non-small cell
lung cancer: evidence beyond predictive biomarkers, file e2188be7-f917-4564-e053-6605fe0a49d6
|
1
|
|
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients, file fd670812-908e-41b4-8971-d9e512884f79
|
1
|
| Totale |
1.078 |